UAE Introduces New Rules to Prevent Medicine Supply Monopolies

The Emirates Drug Establishment has introduced a protocol requiring pharmaceutical companies operating in the UAE to appoint more than one authorised agent for each medical product marketed in the country.
The measure is designed to prevent monopolistic practices and reduce the impact of supply chain disruptions caused by emergencies or operational challenges. By mandating multiple authorised agents per product, the framework aims to maintain market competition and ensure continuous nationwide access to essential medicines.
The requirement applies as a system-level condition for companies marketing medical products in the UAE. It seeks to limit dependency on single distributors and strengthen availability even when global or logistical pressures affect supply chains.
According to the regulator, the protocol forms part of broader efforts to diversify supply chains, enhance regulatory efficiency and create a flexible legislative environment that supports pharmaceutical market sustainability and public health protection.